One study links S100A9 to pulmonary hypertension in humans with chronic obstructive pulmonary disease. In mice, S100A9 increases immune cell recruitment, while aerobic exercise decreases S100A9 in hypoxia-induced pulmonary hypertension.
27 findings in 18 papers from 2016 to 2026, 6 of them since May 2026
The findings reach people, from one lab or study. 15 independent labs in 6 countries.
“the predictive value of monocyte count was associated with significant upregulation of core monocyte/macrophage genes (e.g., CD14, S100A9) during the acute phase”
Cells, mice and humans: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
Includes the processes named after it and trials of drugs aimed at it.
15 independent labs in 6 countries
Funders: National Institutes of Health and others
2 of 26 findings with company ties
Humans18
Animals33
Cells3
In silico2
Interventions
3
Aerobic exercise
↓downin mice1
1 study
Aerobic exercise decreases S100A9 in hypoxia-induced pulmonary hypertension.
“Transcriptomic profiling revealed a marked suppression of inflammatory pathways, with S100A9 identified as the most significantly regulated factor.”
“2.3 and 2.9-fold upregulation of S100a8 and S100a9, respectively, in aged burn-injured mice relative to both young groups and aged sham-injured mice (p < 0.05)”
S100A9 increases cellular senescence in human cells.
“Further treatment of epithelial cells and fibroblasts with recombinant S100A9 resulted in increased senescence and ECM expression, including identified proteins NID1 and FBLN1.”
S100A9 increases extracellular matrix remodeling in human cells.
“Further treatment of epithelial cells and fibroblasts with recombinant S100A9 resulted in increased senescence and ECM expression, including identified proteins NID1 and FBLN1.”
S100A9 induces LINE1 de-repression in human cells (nuclear-translocated S100A9 at parturition).
“where S100A9 causes heterochromatin erosion via segregation of heterochromatin maintenance proteins, resulting in Long Interspersed Nuclear Element-1 (LINE1) de-repression at parturition”
Cellsnuclear-translocated S100A9 at parturitionamnion fibroblasts
Mitochondrial DNA copy number is linked with lower S100A9 in humans (moderate-severe ischemia in chronic coronary artery disease) (FC=-.41, p=3.32e-10).
“DGE revealed downregulation of inflammatory genes in the mtDNA-CN group, including S100A9 (FC=-.41, p=3.32e-10)”
Humansmoderate-severe ischemia in chronic coronary artery diseasewhole bloodn = 594
S100A9 is associated with pulmonary hypertension in patients with chronic obstructive pulmonary disease associated with PH.
“increased S100A9 expression was validated in pulmonary fibrosis-induced PH and in patients with chronic obstructive pulmonary disease associated with PH.”
Humansin patients with chronic obstructive pulmonary disease associated with PH
Monocyte count is associated with S100A9 in humans (acute phase (1 day)).
“the predictive value of monocyte count was associated with significant upregulation of core monocyte/macrophage genes (e.g., CD14, S100A9) during the acute phase”
Cardiovascular conditions affected 28.2% of cancer survivors with obesity, versus 15.6% of adults with obesity alone, despite lower levels of an inflammation marker.Cardiovascular conditions affected 28.2% of cancer survivors with obesity, versus 15.6% of adults with obesity alone, despite lower levels of an inflammation marker.
Experiments on skin removed from older mice suggested that substances released by blood immune cells could partly counter age-related changes.Experiments on skin removed from older mice suggested that substances released by blood immune cells could partly counter age-related changes.